Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinical guide to the regulatory status of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), covering FDA decisions, compounding pharmacy rules, dietary supplement classification, and safety data.
Read clinical reviewAnalysis of FDA FAERS and CAERS safety signal data for nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), including clinical trial adverse event profiles and post-market surveillance limitations.
Read clinical reviewCurrent regulatory status of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) across major markets including FDA classification, EMA position, TGA scheduling, and dietary supplement rules.
Read clinical reviewA complete regulatory timeline for nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) from 2020 through 2026, covering FDA determinations, supplement status, clinical trial evidence, and current labeling rules.
Read clinical reviewHow the FDA and EMA classify nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), including supplement status, novel food authorization, clinical evidence, and what consumers need to know.
Read clinical reviewCurrent regulatory status of NMN and NR (nicotinamide mononucleotide and nicotinamide riboside), active clinical trials, FDA decisions, and the next-generation NAD+ precursor pipeline.
Read clinical review